| PRECLINICAL | evidence | Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction. | Tirzepatide | — | 2026-06-29 |
| PRECLINICAL | evidence | Can the NHS afford Mounjaro? It spent pound574m on the jab last year despite most eligible patients not getting it. | Mounjaro | — | 2026-06-28 |
| PRECLINICAL | evidence | [The role of obesity and weight reduction in obstructive sleep apnea]. | Tirzepatide | Weight & fat loss | 2026-06-28 |
| PRECLINICAL | evidence | GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus. | Tirzepatide | Glycemic control | 2026-06-27 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis. | Tirzepatide | — | 2026-06-26 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis. | Tirzepatide | — | 2026-06-26 |
| PRECLINICAL | evidence | Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide? | Tirzepatide | — | 2026-06-25 |
| PRECLINICAL | evidence | Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. | Tirzepatide | — | 2026-06-25 |
| PRECLINICAL | evidence | Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials. | Tirzepatide | — | 2026-06-25 |
| PRECLINICAL | evidence | Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. | Tirzepatide | — | 2026-06-25 |
| PRECLINICAL | evidence | Peripheral neuropathic symptoms with GLP-1 receptor agonists: Insights from a large real-world cohort. | Tirzepatide | — | 2026-06-24 |
| PRECLINICAL | evidence | Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation. | Tirzepatide | — | 2026-06-24 |
| PRECLINICAL | evidence | Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception. | Tirzepatide | Liver health | 2026-06-24 |
| PRECLINICAL | evidence | Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes. | Tirzepatide | — | 2026-06-23 |
| PRECLINICAL | evidence | Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells. | Tirzepatide | — | 2026-06-23 |
| PRECLINICAL | evidence | Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study. | Tirzepatide | — | 2026-06-23 |
| PRECLINICAL | evidence | Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency. | Tirzepatide | Glycemic control | 2026-06-23 |
| PRECLINICAL | evidence | Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases. | Tirzepatide | — | 2026-06-22 |
| PRECLINICAL | evidence | Residual gastric content after tirzepatide discontinuation: is one week enough? | Tirzepatide | — | 2026-06-22 |
| PRECLINICAL | evidence | Long-term effects of weight-reducing drugs in people with hypertension. | Tirzepatide | — | 2026-06-19 |
| PRECLINICAL | evidence | Functional segregation of body-brain signals in the area postrema. | Tirzepatide | — | 2026-06-19 |
| PRECLINICAL | evidence | Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients. | Tirzepatide | — | 2026-06-18 |
| PRECLINICAL | evidence | Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Tirzepatide | — | 2026-06-18 |
| PRECLINICAL | evidence | Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists. | Tirzepatide | — | 2026-06-18 |
| PRECLINICAL | evidence | Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention. | Tirzepatide | Glycemic control | 2026-06-18 |
| PRECLINICAL | evidence | Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning. | Tirzepatide | — | 2026-06-18 |
| PRECLINICAL | evidence | Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation. | Tirzepatide | — | 2026-06-17 |
| PRECLINICAL | evidence | Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. | Tirzepatide | — | 2026-06-17 |
| PRECLINICAL | evidence | DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Tirzepatide for Obesity in Adults >/= 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis. | Tirzepatide | — | 2026-06-16 |
| PRECLINICAL | evidence | SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. | Tirzepatide | — | 2026-06-15 |
| PRECLINICAL | evidence | Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network. | Tirzepatide | — | 2026-06-15 |
| PRECLINICAL | evidence | Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data. | Tirzepatide | — | 2026-06-14 |
| PRECLINICAL | evidence | Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. | Tirzepatide | — | 2026-06-14 |
| PRECLINICAL | evidence | Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. | Tirzepatide | — | 2026-06-12 |
| PRECLINICAL | evidence | Tirzepatide in type 1 diabetes: beyond mere weight loss. | Tirzepatide | — | 2026-06-11 |
| PRECLINICAL | evidence | Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity. | Tirzepatide | — | 2026-06-11 |
| PRECLINICAL | evidence | SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. | Tirzepatide | Liver health | 2026-06-10 |
| PRECLINICAL | evidence | Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review. | Tirzepatide | — | 2026-06-09 |
| PRECLINICAL | evidence | Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity. | Tirzepatide | — | 2026-06-09 |
| PRECLINICAL | evidence | The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-06-09 |
| PRECLINICAL | evidence | GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. | Tirzepatide | — | 2026-06-07 |
| PRECLINICAL | evidence | Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like-Peptide-1 Use Following 10-Session Cognitive-Behavioural Therapy for Binge-Eating Disorder: A Single-Case Experimental Design. | Tirzepatide | — | 2026-06-06 |
| PRECLINICAL | evidence | Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis. | Tirzepatide | — | 2026-06-05 |
| PRECLINICAL | evidence | A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response. | Tirzepatide | — | 2026-06-05 |